Please login (Members) to view content or
(Nonmembers) this article.
2

Average: 2 (1 vote)

CNE Article

Developing Infrastructure: Managing Patients With Cancer Undergoing CAR T-Cell Therapy


Elizabeth Halton
Diane Llerandi
Claudia Diamonte
Hilda Quintanilla
Donna Miale-Mayer
CJON 2017, 21(2), 35-40 DOI: 10.1188/17.CJON.2.35-40

Background: The introduction of chimeric antigen receptor (CAR) T-cell therapy has created challenges and opportunities for nurses. Clinical nurses must be educated on new treatment modalities to recognize toxicity symptoms and to support the therapy moving forward. 


Objectives: This article will discuss nursing leadership and interventions to standardize care and ensure patient safety while receiving CAR T cells. 


Methods: Using evolving experience, an interprofessional team created standards of care and identified common toxicities and best practices for their management. Electronic documentation forms were designed, which led to the development of a new research infrastructure to care for patients.


Findings: The ability to safely manage patients on CAR T-cell treatments has improved. The new infrastructure supported clinicians and scientists in transforming the outcomes of diseases with bleak prognoses, which is possible only with strong nursing leadership.


Earn contact hours: ONS members can receive free CNE for reading this article and completing an evaluation online. To do so, click HERE or visit cjon.ons.org/cne to access a current list of all available activities. This article's CNE is available for two years from the date of publication.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or